Valereum Plc Regulatory News (VLRM.PL)

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

11/06/25

Valereum Plc

("Valereum", "VLRM" or the "Company")

Valereum Plc Board Changes and Proposed Appointments

Valereum Plc (AQSE: VLRM) announces that Nick Cowan will be stepping down as CEO, with immediate effect, following the unsuccessful completion of the DMC deal. We would like to extend our sincere gratitude to Nick for his leadership and dedication during his time with the Company, and we wish him all the best in his future endeavours. A total of 10,000,000 warrants previously allocated to Nick Cowan have been cancelled.

In addition, Valereum is pleased to announce the following proposed appointments. Each appointment is subject to the completion of customary due diligence checks by the Company's advisers. A further announcement will be made in due course, including any disclosures required under AQSE rule 4.9, should they be applicable.

Proposed Appointee 1 - Matthew Ripperger as Non-Executive Director

Based in New York, Matt has over 25 years' experience in investment management and expansive healthcare expertise. His focus is on building long-term value through deep industry knowledge, data-driven insights and appropriate capital allocation to enhance value for all shareholders. Matt was Managing Director at Harbert Stoneview, prior to which he co-headed healthcare investments at TimesSquare Capital and Glenview Capital Management, including serving on the Board of Tenet Healthcare. Matt began his career at Smith Barney as an analyst in the healthcare investment banking group, and held research roles at UBS Warburg, J.P. Morgan, and Citigroup-earning industry recognition, including a ranking on the Institutional Investor list.

Proposed Appointee 2 - Grant Gischen as Non-Executive Director

Grant is an experienced venture capital investor and strategic advisor with a global track record across deep tech and the energy transition. He is Co-Founder and Partner at Energy Revolution Ventures (ERV), a UK-based VC firm investing in early-stage technologies in hydrogen and renewable fuels, carbon capture, energy storage and advanced materials. At ERV, he has led capital raising efforts, overseen fund governance, advised emerging companies, and helped shape portfolio strategy.

He began his career at Bain & Company, where he supported clients across private equity transactions, digital transformation, energy transition, and infrastructure development.

Grant has extensive experience in corporate finance, M&A and cross-border transactions across diverse sectors and markets. He brings deep investment and strategic expertise to support Valereum's growth in digital asset infrastructure and tokenisation.

Proposed Appointee 3 - John Evans as Board Advisor

John Evans has joined Valereum in a US advisory capacity, and will work closely with Matt Ripperger to support the company's US growth strategy and listing roadmap.

Further changes to the Board

- Gary Cottle will step up from a Non-Executive Director to Executive Director.

- Karl Moss will step down from the Board, but retains his position as Chief Financial Officer.

- Peter Sekhon will step down from the Board, and assume responsibility for a new role, Business Development, while continuing his Investor Relations responsibilities.

These Board changes have been made in the best interests of the Company and its shareholders. Valereum will initiate the process of appointing a new Chief Executive Officer and expects to announce a replacement in due course. In the interim, the Board remains focused on executing the Company's vision and operational priorities.

Chairman of Valereum Plc, James Formolli, comments:

"Valereum is now heading for the global stage, and the proposed Board changes emphasise the expertise and experience required to take the next step. On a personal note, I would like to firstly thank Nick for his hard work and efforts as CEO and wish him all the best for the future. Secondly, to Pete for his continued support, enthusiasm, and devotion to Valereum. And finally, Karl. His commitment to the cause, work ethic and attitude are exemplary, and I cannot thank him enough for his ongoing dedication to "delivering" the bigger picture. These are exciting times for Valereum and growth sometimes results in difficult decisions, both personally and professionally. The changes made reflect that, and I believe we are now better placed to take advantage of an exploding market. It became abundantly clear during the negotiations to conclude the DMC deal that we were "underselling" the business. DMC was given a deadline and they failed to deliver on their obligation. Fortunately for us, it has played out in our favour. We recently announced strategic investments, with minimal dilution to Valereum, in DigiShares and Blubird, and a strategic partnership with Fideum. All 3 are world leaders in their field and are expertly helmed by Claus, Corey and Ana. Grant and Matt's appointments to the Board confirm our commitment to growth and our ability to attract tier 1 professionals who will add weight and credibility to Valereum's onward journey."

Further updates to follow.

For more information, and the chance to have your questions directly answered by the management team, please head to our interactive investor hub via: Investor Hub.

For further information, please contact:

The Directors of the Company accept responsibility for the contents of this announcement.

For more information, please visit the Company's website at www.vlrm.com

Navigate to our Interactive Investor
hub here: Sign Up